At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Aug 6, 2026 at 07:48 ET
argenx has commenced a tender offer to acquire all outstanding shares of Forte Biosciences for $77.00 per share in cash, a deal valued at an undisclosed total amount. The offer, supported by Forte's Board, is subject to a minimum tender condition of more than 50% of shares and HSR clearance, with no financing condition. This acquisition adds Forte's anti-CD122 antibody candidate FB102 to argenx's immunology pipeline, representing a strategic expansion into a new autoimmune target.
- argenx commenced a tender offer for Forte Biosciences at $77.00 per share in cash.
- The offer is subject to a minimum condition of more than 50% of shares tendered and HSR clearance.
- Forte's Board recommends the offer; no stockholder vote is required under Delaware law.
- The acquisition adds FB102, an anti-CD122 antibody, to argenx's pipeline.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access